Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
NCT02065596Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2015
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludarabine in sickle cell disease (SCD), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Probability of Engraftment at 42 days. Started Oct 2015; status: completed.
02
Drugs
fludarabine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02065596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065596.